Investigating PPT2's role in ovarian cancer prognosis and immunotherapy outcomes

• Published in: Journal of ovarian research 2024-10, Vol.17 (1), p.198-17, Article 198
• Main Authors: Xu, Hui, Zhang, Yan, Xie, Zhen, Xie, Xiao-Feng, Qiao, Wen-Lan, Wang, Miao, Zhao, Bei-Bei, Hua, Tian
• Format: Article
• Language: English
• Subjects: B cells; Biomarkers, Tumor - genetics; Cancer; Chemotherapy; China; Development and progression; Drug therapy; Female; Gene expression; Gene Expression Regulation, Neoplastic; Genes; Genetic aspects; Genomes; Genomics; Health aspects; Humans; Immunotherapy; Immunotherapy - methods; Immunotherapy response; Medical research; Medicine, Experimental; Mortality; Ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - immunology; Ovarian Neoplasms - mortality; Ovarian Neoplasms - therapy; Physiological aspects; PPT2; Prognosis; RNA; RNA sequencing; Thiolester Hydrolases - genetics; Thiolester Hydrolases - metabolism; Tumor microenvironment
• ISSN: 1757-2215; 1757-2215
• DOI: 10.1186/s13048-024-01527-9

Ovarian cancer (OC) remains the primary cause of mortality among gynecological malignancies, and the identification of reliable molecular biomarkers to prognosticate OC outcomes is yet to be achieved. The gene palmitoyl protein thioesterase 2 (PPT2), which has been sparsely studied in OC, was closely associated with metabolism. This study aimed to determine the association between PPT2 expression, prognosis, immune infiltration, and potential molecular mechanisms in OC. We obtained the RNA-seq and clinical data from The Cancer Genome Atlas (TCGA), The Genotype-Tissue Expression (GTEx) and Gene Expression Omnibus (GEO) databases, then Kaplan-Meier analysis, univariate Cox regression, multivariate Cox regression, nomogram, and calibration were conducted to assess and verify the role of PPT2. Gene set enrichment analysis (GSEA) was used to figure out the closely correlated pathways with PPT2. Overexpression experiment was performed to explore the function of PPT2. Our findings showed that PPT2 mRNA expression was apparent down-regulation in OC tissue compared to normal ovarian tissues in TCGA, GTEx datasets, and GEO datasets. This differential expression was also confirmed in our in-house datasets at both the mRNA and protein levels. Decreased PPT2 expression correlated with lower survival rates in TCGA, several GEO datasets, and our in-house datasets. Multivariate analysis revealed that PPT2 was an independent factor in predicting better outcomes for OC patients in TCGA and GEO. A negative correlation was revealed between immune infiltration and PPT2 expression through Single-sample GSEA (ssGSEA). Additionally, PPT2 was negatively correlated with an up-regulated immune score, stromal score, and estimate score, suggesting that patients with low PPT2 expression might benefit more from immunotherapy. Numerous chemical agents showed lower IC50 in patients with high PPT2 expression. In single-cell RNA sequencing (scRNA-seq) analysis of several OC datasets, we found PPT2 was mainly expressed in endothelial cells. Furthermore, we found that PPT2 inhibited OC cell proliferation in vitro. Our results demonstrated that PPT2 was considered a favorable prognostic biomarker for OC and may be vital in predicting response to immunotherapy and chemotherapy. Further research was needed to fully understand the relationship between PPT2 and immunotherapy efficacy in OC patients.